Mounjaro
(tirzepatide)
Once-weekly injection. The only dual-action GIP and GLP-1 treatment, with the strongest results seen in clinical trials — average weight loss of 20% or more at higher doses over 72 weeks. MHRA-licensed.
LICENSED PHARMACY & UK-LICENSED DOCTORS · FREE DISCREET DELIVERY
SEMAGLUTIDE 2.4 MG · NOVO NORDISK · WEEKLY INJECTION
WEGOVYFLEXPEN
1WEEKLY DOSE
15AVG % LOSS
68WEEKS - STEP 1
MHRALICENSED
Free discreet delivery
*Based on manufacturer trials. Individual results vary.
Wegovy is a once-weekly semaglutide injection and one of the most prescribed weight loss treatments in the world. In its landmark trial, adults lost an average of around 15% of their body weight — and Wegovy remains the only weight loss injection with dedicated trial evidence of reduced heart attack and stroke risk in people with cardiovascular disease.
ABOUT THE MEDICATION
WHAT IS WEGOVY?
Wegovy is the brand name for semaglutide 2.4 mg, made by Novo Nordisk. Licensed by the MHRA for weight management since 2023, it's the medicine that brought GLP-1 treatment into the mainstream: hundreds of thousands of UK patients and millions worldwide have used it, giving it one of the deepest real-world evidence bases in the category.
It's licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² and above with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Semaglutide is the same active ingredient found in Ozempic (licensed for type 2 diabetes at lower doses) and the new Wegovy tablets — the weekly 2.4 mg injection is the original weight-management formulation.
KEY BENEFITS
ONCE WEEKLY
A pre-filled pen for once-weekly injection under the skin of the stomach, thigh or upper arm, with each pen strength covering four weekly doses.
~15% AVERAGE WEIGHT LOSS
Average weight loss was 14.9% with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks in STEP 1.
PROVEN CARDIOVASCULAR BENEFIT
SELECT showed semaglutide 2.4 mg reduced major adverse cardiovascular events — heart attack, stroke and cardiovascular death — by around 20% versus placebo.
MHRA-LICENSED
Licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² and above with at least one weight-related condition.
How it works
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Wegovy is clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Wegovy is clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
CHECK IF YOU QUALIFY FOR GLP-1 WEIGHT LOSS TREATMENT
GLP-1 weight loss treatments are licensed for adults who meet one of the following criteria, alongside a reduced-calorie diet and increased physical activity:
- A BMI of 30 kg/m² or above (obesity), or
- A BMI of 27 kg/m² or above (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea or cardiovascular disease.
BMI thresholds may be adjusted for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who are at higher cardiometabolic risk at lower BMIs.
Meeting the BMI criteria alone doesn't guarantee suitability — our prescribers review your full medical history. GLP-1 treatments are not suitable during pregnancy or breastfeeding, or for people with a personal or family history of medullary thyroid carcinoma or MEN 2, among other contraindications your prescriber will assess.
Weight loss treatment eligibility
- 1Basic Info
- 2Ethnic group
- 3Health conditions
- 4Results
Basic Info
What is your height?
What is your weight?
WEGOVY® INJECTION
- Proven cardiovascular benefit (SELECT)
- FlexTouch pen — four weekly doses per pen
- Once weekly
- ~15% average weight loss
Proven cardiovascular benefit (SELECT)
FlexTouch pen — four weekly doses per pen
Once weekly
~15% average weight loss
TRIAL WEIGHT LOSS RESULTS
~15%
average weight loss over 68 weeks in the STEP 1 trial (semaglutide 2.4 mg)
- MOUNJARO (TIRZEPATIDE)~21%
- WEGOVY TABLETS~13-14%
- WEGOVY INJECTION~15%
Cross-trial figures are not head-to-head comparisons. Individual results vary; all trial results were alongside lifestyle support.
What is it?
Same Molecule, Different Licence
Semaglutide is the same active ingredient found in Ozempic (licensed for type 2 diabetes at lower doses) and the new Wegovy tablets — the weekly 2.4 mg injection is the original weight-management formulation.
Same molecule, different licence and dose: Ozempic is for type 2 diabetes (up to 2 mg weekly); Wegovy is for weight management (up to 2.4 mg weekly). Prescribing Ozempic for weight loss is off-licence and squeezes supply for diabetes patients — Wegovy is the right route.
The FlexTouch Pen
Wegovy comes as the FlexTouch pen: a pre-filled pen for once-weekly injection under the skin of the stomach, thigh or upper arm, with each pen strength covering four weekly doses.
How It Works
How Wegovy Works
Semaglutide mimics GLP-1, the fullness hormone your gut releases after eating. Natural GLP-1 is destroyed within minutes; semaglutide is engineered to last, keeping the signal switched on all week. The effect patients describe most often isn't willpower — it's that the pull of food loosens:
Appetite drops
Smaller portions genuinely satisfy, and snacking urges fade.
Food noise quietens
The background mental chatter about eating turns down — for many patients, the most life-changing effect.
Fullness lasts
Slower stomach emptying means meals hold you for hours.
Blood sugar steadies
Fewer energy dips and crash-driven cravings.
Step by step
HOW TO INJECT WEGOVY
01
Check the pen
Wash your hands; check the pen label, expiry and that the solution is clear and colourless.
02
Attach a new needle
Attach a new needle each time; with each new pen, check the flow as per the leaflet before the first dose.
03
Set dose and site
Turn the dose selector to your prescribed dose, choose a site — stomach (5 cm from the navel), front of thigh, or back of upper arm — and clean the skin.
04
Inject and hold
Insert the needle fully, press and hold the button until the counter shows 0, then count slowly to 6 before withdrawing to ensure the full dose.
05
Dispose and rotate
Dispose of the needle in your sharps bin, recap the pen, and rotate sites weekly.
06
Pick a consistent day
Pick a consistent day ('Wegovy Wednesday' genuinely helps adherence); the day can be changed if at least 2 days separate doses.
Side Effects
FULL PICTURE &
HOW TO MANAGE THEM
Wegovy's side-effect profile is among the best documented in medicine, with millions of patient-years of real-world use. Digestive symptoms dominate, cluster around dose increases, and settle for the large majority:
FREQUENCY
SIDE EFFECTS
WHAT TO DO
VERY COMMON >1 IN 10
Nausea, diarrhoea, constipation, vomiting, headache, fatigue
Smaller slower meals, avoid fatty food, hydrate; symptoms typically fade within days of each dose change
COMMON — UP TO 1 IN 10
Reflux, bloating, burping, dizziness, hair shedding, gallstones, injection-site reactions
Hair shedding reflects rapid weight loss and regrows; report right-sided upper abdominal pain, fever or jaundice promptly
UNCOMMON — UP TO 1 IN 100
Raised heart rate, low blood sugar (mainly with diabetes medicines), delayed stomach emptying symptoms
Reviewed at routine check-ins; adjust diabetes medicines with your clinician
RARE BUT SERIOUS
Pancreatitis, severe allergic reaction, dehydration/kidney injury from prolonged vomiting
Severe persistent abdominal pain (possibly to the back), facial/throat swelling, or inability to keep fluids down: urgent medical help
Surgery and procedures: tell clinicians you're on Wegovy before any planned surgery or sedation — slowed stomach emptying is relevant to anaesthesia, and you may be asked to pause treatment beforehand. Report suspected side effects via the MHRA Yellow Card scheme; our pharmacists are on hand throughout treatment.
The Evidence
Clinical Evidence: What the Trials Show
STEP 1 — The Pivotal Trial
14.9%
average weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks
STEP 1 enrolled 1,961 adults with obesity (or overweight with a comorbidity) without diabetes for 68 weeks. 86% of participants lost at least 5% of their body weight, 69% at least 10%, half at least 15%, and roughly a third 20% or more.
SELECT — The Cardiovascular Landmark
~20%
reduction in major adverse cardiovascular events versus placebo
SELECT followed 17,604 adults with established cardiovascular disease and overweight or obesity (without diabetes) for over three years. Semaglutide 2.4 mg reduced major adverse cardiovascular events — heart attack, stroke and cardiovascular death — by around 20% versus placebo. No other weight loss injection currently holds equivalent licensed evidence.
STEP 5 — Two-Year Durability
~15%
average loss maintained over 104 weeks
Over 104 weeks, participants maintained an average loss of around 15%, demonstrating that results hold with continued treatment rather than fading.
STEP 4 — What Happens If You Stop
20 weeks
the point at which participants were switched to placebo
Participants switched to placebo after 20 weeks regained much of their lost weight over the following year, while those who continued kept losing — the clearest evidence that obesity treatment works like treatment for any chronic condition: it works while you treat it.
Cross-trial figures are not head-to-head comparisons. Individual results vary; all trial results were alongside lifestyle support.
Cross-trial figures are not head-to-head comparisons. Individual results vary; all trial results were alongside lifestyle support.
Dosing
Schedule
Escalating is a clinical decision, not an automatic ladder.
DURATION
WEEKLY DOSE
STAGE
Weeks 1–4
0.25 mg
Starting dose
Weeks 5–8
0.5 mg
Step 2
Weeks 9–12
1 mg
Step 3
Weeks 13–16
1.7 mg
Step 4
Ongoing
2.4 mg
Maintenance
MISSED DOSE
Inject within 5 days of the missed dose if you can; beyond 5 days, skip it and resume on your usual day. Never take two doses to catch up.
Escalation & the 1.7 mg maintenance dose
If a step-up causes troublesome side effects, escalation can be paused or stepped back — and 1.7 mg is a licensed maintenance dose for patients who don't tolerate 2.4 mg. Escalating is a clinical decision, not an automatic ladder.
Progress Over Time
What to Expect:
Your Timeline
Weeks 1–4
0.25 mg
A deliberate tolerance dose. Appetite changes usually appear within the first two weeks; scale movement is modest and that's expected.
Months 2–4
0.5 mg → 1.7 mg
Doses step up monthly; steady, visible loss becomes the norm. Side effects, if any, cluster briefly around each increase.
Months 4–6
1.7–2.4 mg
The steepest phase of the curve for most patients. Protein and strength work matter most here to protect muscle.
Months 6–16
2.4 mg
Continued gradual loss, typically plateauing around the 12–16 month mark near the trial average. A plateau is a new set point, not a failure — maintenance planning starts here.
FULL RANGE
HOW WEGOVY
COMPARES
RELATED TREATMENTS.
Real medication. Real doctors. No inflated prices. Just results.
New — MHRA approved June 2026
Wegovy Tablets
(oral semaglutide)
New for 2026. The UK's first once-daily GLP-1 weight loss tablet, MHRA-approved in June 2026. The same active ingredient as the Wegovy injection, with comparable weight loss in trials — no needles required.
New — MHRA-licensed
Foundayo
(orforglipron)
Eli Lilly's once-daily GLP-1 tablet, approved in the US in April 2026 and now licensed by the MHRA. It can be taken at any time of day, with or without food.
Brand discontinued — generic available
Liraglutide
(Saxenda)
£— / month
Once-daily injection. Branded Saxenda has been discontinued by Novo Nordisk, but generic liraglutide (Nevolat) contains the same medicine at the same dose and remains available for patients established on liraglutide or those it suits clinically.
Price includes medication only, if prescribed. An active FromMars membership is required and billed separately. Membership does not include or guarantee a prescription; medication is not available without a membership.
Drug Interactions
Interactions With Other Medicines
Diabetes medicines
With insulin or sulfonylureas, hypoglycaemia risk increases and those doses often need reduction — coordinate with your diabetes team.
Other oral medicines
Slower stomach emptying can modestly alter absorption; for narrow-window drugs (warfarin, levothyroxine) mention Wegovy so monitoring can be arranged.
Oral contraceptives
Unlike Mounjaro, Wegovy is not considered to reduce contraceptive pill effectiveness — but pregnancy itself must be avoided on treatment, so reliable contraception still matters.
Alcohol
No direct interaction, but it aggravates nausea and adds calories; moderation advised, and many patients find desire for it fades.
WARNINGS
Who Should Not Take Wegovy
DO NOT USE IF ALLERGIC TO SEMAGLUTIDE OR ANY INGREDIENT, PREGNANT OR BREASTFEEDING
Stop at least two months before a planned pregnancy.
NOT RECOMMENDED WITH A HISTORY OF PANCREATITIS
Severe gastrointestinal disease including gastroparesis, or alongside any other GLP-1 medicine (including Ozempic, Rybelsus or Saxenda).
CAUTION IN DIABETIC RETINOPATHY (PATIENTS WITH DIABETES)
Gallbladder disease history, and severe kidney or liver impairment.
NOT LICENSED UNDER 18 IN OUR SERVICE
Screened against eating disorder history during consultation.
Lifestyle
Diet, Lifestyle & Practicalities
- 01
Protein First
Protein first (~1.2–1.6 g/kg target weight daily): protects muscle during rapid loss — the difference between looking lighter and looking well.
- 02
Strength Training
Strength training twice weekly: preserves lean mass and metabolic rate; bodyweight exercises count.
- 03
Hydration
Two litres of water daily: appetite suppression blunts thirst; hydration also eases the three most common side effects.
- 04
Small, Regular Meals
Small, regular meals; gentle fibre increase: prevents both nausea (large/fatty meals) and constipation (the most persistent complaint).
- 05
Storing Your Pens
Store pens at 2–8°C in the fridge; never freeze — a frozen pen must be discarded. In-use pens can stay below 30°C for up to 28 days — covering the pen's four doses with margin.
- 06
Travel & Delivery
Fly with pens in hand luggage (hold can freeze); travel letters available on request; needles and sharps bin supplied with every order. All deliveries ship free, next-day, in validated cold-chain packaging, unbranded.
Don't under-eat: routinely below ~1,200 kcal invites fatigue, hair shedding and nutrient gaps — a daily multivitamin is a sensible safeguard, and our pharmacists can review your intake.
Stopping & Maintenance
Stopping Wegovy & Keeping the Weight Off
STEP 4 showed it plainly: stop treatment without a plan and most lost weight returns within a year, because the appetite biology treatment was suppressing comes back.
What never works is simply stopping and hoping — plan the exit as carefully as the start.
Your Maintenance Options
The realistic options are ongoing maintenance dosing (many patients hold results at 1.7 mg or with extended dose intervals agreed by their clinician), a structured taper with intensified lifestyle support, or a clinician-managed switch.
Houston,
we have answers.
Houston,
we have answers.
Sources
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989–1002.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med 2022;28:2083–2091.
- Rubino D et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021;325:1414–1425.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389:2221–2232.
- Wegovy Summary of Product Characteristics (SmPC), electronic medicines compendium (emc), current version.
- NICE TA875: Semaglutide for managing overweight and obesity.
Pricing
Cost & What's Included
Wegovy is priced per pen (four weekly doses), varying by strength from [£X] at 0.25 mg to [£X] at 2.4 mg. Displayed prices include the prescriber consultation, ongoing pharmacist support, needles, sharps disposal and cold-chain delivery — no hidden fees, no subscription lock-in.
- Prescriber consultation
- Ongoing pharmacist support
- Needles and sharps disposal
- Free cold-chain delivery
- No hidden fees, no subscription lock-in
0.25 mgStarting dose
0.5 mgStep 2
1 mgStep 3
1.7 mgStep 4
2.4 mgMaintenance
READY TO START?
GET WEGOVY®
INJECTION TODAY
Complete a free online consultation and, if appropriate, our GPhC-registered pharmacy will dispense your Wegovy pen with free, temperature-controlled next-day delivery and ongoing clinical support.